rs1057519827
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer.
|
24398047 |
2014 |
rs1057519714
|
|
C |
0.700 |
CausalMutation |
CLINVAR |
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
|
24185512 |
2013 |
rs1057519715
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
|
24185512 |
2013 |
rs1057519716
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
|
24185512 |
2013 |
rs1057519717
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
|
24185512 |
2013 |
rs1057519717
|
|
G |
0.700 |
CausalMutation |
CLINVAR |
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
|
24185510 |
2013 |
rs1057519827
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
|
24185510 |
2013 |
rs1057519827
|
|
C |
0.700 |
GeneticVariation |
CLINVAR |
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
|
24185512 |
2013 |
rs796065354
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Our findings suggest that the K303R ERalpha mutation might be a new predictive marker of response to AIs in mutation-positive breast tumors, and that targeting the PI3K/Akt pathway may be a useful strategy for treating patients with tumors resistant to hormone therapy.
|
19487288 |
2009 |
rs796065354
|
|
|
0.040 |
GeneticVariation |
BEFREE |
Consistent with our previous finding of this somatic ERalpha mutation in breast ductal hyperplasias, we now present evidence that the A908G mutation is present in invasive breast tumors using an optimized sequencing method.
|
17545528 |
2007 |
rs796065354
|
|
|
0.040 |
GeneticVariation |
BEFREE |
These preliminary results suggest that OCs may interact with the ESR1 A908G mutant receptor to drive the development of some breast tumors.
|
17553133 |
2007 |
rs796065354
|
|
|
0.040 |
GeneticVariation |
BEFREE |
The ER-alpha A908G mutation was found more frequently in higher-grade bre</span>ast tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.
|
16280033 |
2005 |
rs1462893414
|
|
|
0.030 |
GeneticVariation |
BEFREE |
These preliminary results suggest that OCs may interact with the ESR1 A908G mutant receptor to drive the development of some breast tumors.
|
17553133 |
2007 |
rs1462893414
|
|
|
0.030 |
GeneticVariation |
BEFREE |
Consistent with our previous finding of this somatic ERalpha mutation in breast ductal hyperplasias, we now present evidence that the A908G mutation is present in invasive breast tumors using an optimized sequencing method.
|
17545528 |
2007 |
rs1462893414
|
|
|
0.030 |
GeneticVariation |
BEFREE |
The ER-alpha A908G mutation was found more frequently in higher-grade bre</span>ast tumors (odds ratio (OR) 2.83; 95% confidence interval (CI) 1.09 to 7.34, grade II compared with grade I), and in mixed lobular/ductal tumors (OR 2.10; 95% CI 0.86 to 5.12) compared with ductal carcinomas, although the latter finding was not statistically significant.
|
16280033 |
2005 |
rs904571820
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A direct sequencing analysis of p53 revealed a p.V173M mutation in exon 5 in both the breast tumor and the ovarian cancer.
|
28662703 |
2017 |